Condition: Ovary Cancer · Peritoneal Cancer · Fallopian Tube Cancer · Sponsor: University of Colorado, Denver
The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.
This description comes directly from the study's public registry record.
Kailey Palmen, BA · 303-724-2435 · kailey.palmen@cuanschutz.edu
Always discuss trial participation with your own doctor first.
| City of Hope Lennar | Irvine, California, United States | Recruiting |
| University of Colorado Hospital | Aurora, Colorado, United States | Recruiting |
| Northwestern Memorial Hospital | Chicago, Illinois, United States | Recruiting |
| University of Pennsylvania Health System, Perelman Center for Advanced Medicine | Philadelphia, Pennsylvania, United States | Recruiting |
| UPMC Magee-Women's Hospital | Pittsburgh, Pennsylvania, United States | Recruiting |
| University of Wisconsin - Carbone Cancer Center - University Hospital | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05887609